This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors Of Upcoming Deadlines In Shareholder Litigation Involving Delcath Systems, Inc., Amyris, Inc., Nam Tai Electronics, Inc. And Accretive Health, Inc.

Holzer Holzer & Fistel LLC reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against Delcath Systems, Inc. (DCTH), Amyris, Inc. (AMRS), Nam Tai Electronics, Inc. (NTE) and Accretive Health, Inc. (AH).

Investors that suffered significant losses investing in any of these companies during the specified times who are interested in potentially serving as lead plaintiff in the respective class actions are encouraged to contact Michael I. Fistel, Jr., Esq. ( mfistel@holzerlaw.com) or Marshall P. Dees, Esq. ( mdees@holzerlaw.com) by email or via toll-free telephone at (888) 508-6832 to discuss their legal rights.

A lead plaintiff is a representative party appointed by the court to act on behalf of other class members in directing the litigation. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Delcath Systems Inc.

A class action lawsuit has been filed on behalf of investors who purchased Delcath (NASDAQ: DCTH) common stock between April 21, 2010 and May 2, 2013, inclusive, alleging the company violated the federal securities laws by, among other things, misrepresenting the status of its New Drug Application for the commercial sale of its Melblez Kit.

The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Eastern District of Pennsylvania, is July 8, 2013. More information about the lawsuit and the firm are available at www.holzerlaw.com.

Amyris, Inc.

A class action lawsuit has been filed on behalf of investors who purchased Amyris, Inc. (NASDAQ: AMRS) common stock between April 29, 2011 and February 8, 2012. The lawsuit alleges the company violated the federal securities laws by issuing false and misleading statements regarding Amyris’s ability to commercially produce Biofene.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs